New prospects for lipid-lowering drugs

Bibliography

• AUWERX J, SCHOONJANS K, FRUCHART J, STAELS B: Transcriptional control of triglyceride metabolism: fi-brates and fatty acids change the expression of the LPL and apoC-III genes by activating the nuclear receptor PPAR. Atherosclerosis (1996) 124:S29–S37.
   Google Scholar
• ••Useful review of a burgeoning area of research.
   Google Scholar
• COMMITTEE OF PRINCIPAL INVESTIGATORS: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Com-mittee of Principal Investigators. Br. Heart J. (1978) 40:1069–1118.
   PubMedGoogle Scholar
• FRICK MH, ELO 0, HAAPA K et al.: Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl. J. Med. (1987) 317:1237–1245.
   Google Scholar
• COMMITTEE OF PRINCIPAL INVESTIGATORS: WHO co-operative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum choles-terol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet (1980) 2:379–385.
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Preven-tion Trial results. I. Reduction in incidence of coronary heart disease. JAMA (1984) 251:351–364.
   Google Scholar
• BLANKENHORN DH, NESSIM SA, JOHNSON RL et al.:Beneficial effects of combined colestipol-niacin ther-apy on coronary atherosclerosis and coronary venous bypass grafts [published erratum appears in JAMA 1988;259(18):2698]. JAMA (1987) 257:3233–3240.
   PubMed Web of Science ®Google Scholar
• CASHIN HEMPHILL L, MACK WJ, POGODA JM et al.: Bene-ficial effects of colestipol-niacin on coronary athero-sclerosis. A 4-year follow-up. JAMA (1990) 264:3013–3017.
   Google Scholar
• BRADFORD RH, SHEAR CL, CHREMOS AN et al: Ex-panded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipopro-teins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. (1991) 151:43–49.
   Google Scholar
• LATIES AM, SHEAR CL, LIPPA EA et al: Expanded clinical evaluation of lovastatin (EXCEL) study results. II. As-sessment of the human lens after 48 weeks of treat-ment with lovastatin. Am. J. Cardiol. (1991) 67:447–453.
   Google Scholar
• BLANKENHORN DH, AZEN SP, KRAMSCH DM et al.: Coro-nary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann. Intern. Med. (1993) 119:969–976.
   Google Scholar
• WATERS D, HIGGINSON L, GLADSTONE P et al.: Effects ofmonotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as as-sessed by serial quantitative arteriography. The Cana-dian Coronary Atherosclerosis Intervention Trial. Circulation (1994) 89:959–968.
   PubMed Web of Science ®Google Scholar
• Effect of simvastatin on coronary atheroma: the Multi-centre Anti-Atheroma Study (MAAS) [published erra-tum appears in Lancet 1994 344(8924):762). Lancet (1994) 344:633–638.
   PubMedGoogle Scholar
• PITT B, MANCINI GB, ELLIS SG et al.: Pravastatin limita-tion of atherosclerosis in the coronary arteries (PLAC 0: reduction in atherosclerosis progression and clini-cal events. PLAC I investigation. J. Am. Coll. Cardiol (1995) 26:1133–1139.
   PubMed Web of Science ®Google Scholar
• JUKEMA JW, BRUSCHKE AV, VAN BOVEN AJ et al: Effectsof lipid lowering by pravastatin on progression and re-gression of coronary artery disease in symptomatic men with normal to moderately elevated serum cho-lesterol levels. The Regression Growth Evaluation Sta-tin Study (REGRESS). Circulation (1995) 91:2528–2540.
   PubMed Web of Science ®Google Scholar
• HERD JA, BALLANTYNE CM, FARMER JA et al.: Effects offluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. (1997) 80:278–286.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• •First proof that lowering LDL cholesterol decreases total mortality in hypercholesterolaemic patients with coronary patients.
   Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Pre-vention Study Group. New Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• •First evidence that statins are effective in the primary pre-vention of CHD.
   Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al: The effect of pra- vastatin on coronary events after myocardial infarc-tion in patients with average cholesterol levels. New Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• •Trial showing that statins are effective in secondary preven-tion of CHD even in normolipidaemic subjects.
   Google Scholar
• ANDREWS TC, RABY K, BARRY J et al.: Effect of choles-terol reduction on myocardial ischemia in patients with coronary disease. Circulation (1997) 95:324–328.
   PubMed Web of Science ®Google Scholar
• ODRISCOLL G, GREEN D, TAYLOR RR: Simvastatin, anHMG-Coenzyme A reductase inhibitor, improves en-dothelial function within 1 month. Circulation (1997) 95:1126–1131.
   PubMed Web of Science ®Google Scholar
• •Study showing that short-term LDL-lowering results in im-proved arterial endothelial function.
   Google Scholar
• VOGEL RA, CORRETTI MC, PLOTNICK GD: Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am. J. Cardiol (1996) 77:37–40.
   PubMed Web of Science ®Google Scholar
• TAMAI 0, MATSUOKA H, ITABE H et al: Single LDL apheresis improves endothelium-dependent vasodila-tation in hypercholesterolemic humans. Circulation (1997) 95:76–82.
   PubMed Web of Science ®Google Scholar
• •Demonstration of improved arterial endothelial function with hours lowering LDL by apheresis.
   Google Scholar
• LEUNG WH, LAU CP, WONG CK: Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholes-terolaemic patients. Lancet (1993) 341:1496–1500.
   PubMed Web of Science ®Google Scholar
• NAWROCKI JW, WEISS SR, DAVIDSON MH et al: Reduc-tion of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. (1995) 15:678–682.
   PubMed Web of Science ®Google Scholar
• •First description of remarkable clinical efficacy of atorvasta-tin in lowering LDL cholesterol.
   Google Scholar
• BAKKER-ARKEMA RG, DAVIDSON MH, GOLDSTEIN RJ et al.: Efficacy and safety of a new HMG-CoA reductase in-hibitor, atorvastatin, in patients with hypertriglyc-eridemia. JAMA (1996) 275:128–133.
   PubMed Web of Science ®Google Scholar
• OOI TC, HEINONEN T, ALAUPOVIC P et al.: Efficacy and safety of a new hydroxy-methylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with com-bined hyperlipidaemia: comparison with fenofibrate. Arterioscler. Thromb. Vasc. Biol. (1997) 17:1793–1799.
   Google Scholar
• MARAIS AD, NAOUMOVA RP, FIRTH JC et al: Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholes-terolemia. J Lipid Res. (1997) 38:2071–2078.
   PubMed Web of Science ®Google Scholar
• ••Evidence that atorvastatin lowers LDL in homozygous FH bydecreasing its secretion, based on kinetic analysis of post-apheresis rebound curves.
   Google Scholar
• MARAIS AD, FIRTH JC, BATEMAN ME et al.: Atorvastatin: an effective lipid-modifying agent in familial hyper-cholesterolemia. Arterioscler. Thromb. Vasc. Biol. (1997) 17:1527–1531.
   PubMed Web of Science ®Google Scholar
• DART A, JERUMS G, NICHOLSON G et al: A multicenter,double-blind, one-year study comparing safety and ef-ficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardiol (1997) 80:39–44.
   PubMed Web of Science ®Google Scholar
• DAVIDSON M, MCKENNY J, STEIN E etal.: Comparison ofone-year efficacy and safety of atorvastatin versus lo-vastatin in primary hypercholesterolemia. Am. J. Car-diol. (1997) 79:1475–1481.
   Google Scholar
• BERTOLINI S, BITTOLO BON G, CAMPBELL LM et al: Effi-cacy and safety of atorvastatin compared to pravasta-tin in patients with hypercholesterolemia. Atherosclerosis (1997) 130:191–197.
   PubMed Web of Science ®Google Scholar
• AUERBACH BJ, KRAUSE BR, BISGAIER CL, NEWTON RS: Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis (1995) 115:173–180.
   PubMed Web of Science ®Google Scholar
• NAOUMOVA RP, DUNN S, RALLIDIS L et al.: Prolonged in-hibition of cholesterol synthesis explains the efficacy of atorvastatin. J. Lipid Res. (1997) 38:1496–1500.
   PubMed Web of Science ®Google Scholar
• ••Comparison of plasma and urinary mevalonic acid after sin-gle doses of simvastatin and atorvastatin shows more pro-longed decrease in cholesterol synthesis with the latter drug.
   Google Scholar
• THOMPSON GR, NAOUMOVA RP, WATTS GF: Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res. (1996) 37:439–447.
   PubMed Web of Science ®Google Scholar
• BISCHOFF H, ANGERBAUER R, BENDER J et al: Cerivasta-tin: pharmacology of a novel synthetic and highly ac-tive HMG-CoA reductase inhibitor. Atherosclerosis (1997) 135:119–130.
   PubMed Web of Science ®Google Scholar
• •Description of in vitro properties and potency of the latest HMG CoA reductase inhibitor, cerivastatin.
   Google Scholar
• STEIN E, SPRECHER D, ALLENBY KS et al.: Cerivastatin, a new potent synthetic HMG CoA reductase inhibitor: ef-fect of 0.2 mg daily in subjects with primary hypercho-lesterolemia. J. Cardiovasc. Pharmacol. Therap. (1997) 2:7–16.
   Google Scholar
• NAKAYA N, KOJIMA J, KIMATA H, KUWAHATA R, NARU-SIMA H: NK-104: efficacy and tolerance of a new syn-thetic HMG-CoA reductase inhibitor in hypercholesterolemic volunteers. 12th Int. Symp. Drugs Affect. Lipid Metab. Houston, Texas, USA, (1995) 137.
   Google Scholar
• SLISKOVIC DR, PICARD JA: Squalene synthase inhibi-tors. In: Emerging Drugs. Bowman WC, Fitzgerald D, Warne P. (1997) 2:93–107.
   Google Scholar
• ROSENBLUM SB, HUYNH T, DAVIS H et al.: Discovery of SCH-58235, a potent orally active inhibitor of choles-terol absorption. 12th Int. Symp. Drugs Affect. Lipid Me-tab. Houston, Texas, USA (1995) 6.
   Google Scholar
• HAINER JW, HUNNINGHAKE DB, BENEDEK IH etal.: DMP504, a novel hydrogel bile acid sequestrant: III. Safety, tolerability, and cholesterol-lowering effects in healthy hypercholesterolemic subjects. Drug Dev. Res. (1997) 41:76–84.
   Google Scholar
• HOMMA Y, KOBAYASHI T, OZAWA H, YAMAGUCHI H,SAKANE H: Effects of a new bile acid sequestering resin, MCI-196 on plasma lipoprotein subfractions. 12th Int. Symp. on Drugs Affect. Lipid Metab. Houston, Texas, USA (1995) 59.
   Google Scholar
• ICHIHASHI T, ISAWA M, MIYATA K et al. Mechanism ofhypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption. J. Pharmacol. Exp. Ther. (1998) 284:43–50.
   PubMed Web of Science ®Google Scholar
• MUSANTI R, GIORGINI L, LOVISOLO P et al: Inhibition ofacyl-CoA: cholesterol acyltransferase decreases apoli-poprotein B-100-containing lipoprotein secretion from HepG2 cells. J. Lipid Res. (1996) 37:1–14.
   PubMed Web of Science ®Google Scholar
• •Experimental evidence which suggests that ACAT activity may be a determinant of hepatic lipoprotein secretion.
   Google Scholar
• BURNETT JR, WILCOX LI TELFORD DE et al.: Hepaticapolipoprotein B secretion, in vivo, is decreased by the ACAT inhibitor CI-1011 in miniature pigs. Circulation (1997) 96:1–544
   Google Scholar
• BOCAN TMA, ROSEBURY WS, MUELLER SB et al.: MightACAT inhibitors promote development of a stable plaque morphology? Circulation (1997) 96:1–491
   Google Scholar
• ZHONG S, SHARP DS, GROVE JS et al.: Increased coro-nary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. (1996) 97:2917–2923.
   PubMed Web of Science ®Google Scholar
• MAROTTI KR, CASTLE CK, BOYLE TP etal.: Severe athero-sclerosis in transgenic mice expressing simian choles-teryl ester transfer protein. Nature (1993) 364:73–75.
   Google Scholar
• FIELDING CJ, HAVEL RJ: Cholesteryl ester transfer pro-tein: friend or foe? J. Clin. Invest. (1996) 97:2687–2688.
   Google Scholar
• KUIVENHOVEN JA, JUKEMA JW, ZWINDERMAN AH et al: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl. J. Med. (1998) 338:86–93.
   PubMed Web of Science ®Google Scholar
• ••Recent analysis of samples from REGRESS showing effect ofa CETP polymorphism on CETP activity and progression of coronary atherosclerosis.
   Google Scholar
• HARRIS WS, GINSBERG HN, ARUNAKUL N et al.: Safetyand efficacy of Omacor in severe hypertriglyceride-mia. j Cardiovasc. Risk (1997) 4:385–391.
   PubMedGoogle Scholar
• PEDERSEN TR, KJEKSHUS J: Results support AHA guide-lines to reduce LDL-cholesterol to less than 100 mg/di in patients with CHD. Circulation (1997) 96:1–717.
   Google Scholar
• PACKARD CJ: Relationship between LDL-C changes andCHD event reduction with pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Cir-culation (1997) 96:1–107
   Google Scholar
• ERICSSON C, HAMSTEN A, NILSSON J et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post-infarction patients. Lancet (1996) 347:849–853.
   PubMed Web of Science ®Google Scholar
• •Small, but important study showing angiographic benefit during treatment with bezafibrate, despite lack of any change in LDL cholesterol.
   Google Scholar
• ERICSSON C, NILSSON J, GRIP L, SVANE B, HAMSTEN A: Effect of bezafibrate treatment over five years on coro-nary plaques causing 20% to 50% diameter narrowing he Bezafibrate Coronary Atherosclerosis Interven-tion Trial (BECAIT)). Am. J. Cardiol (1997) 80:1125–1129.
   PubMed Web of Science ®Google Scholar
• ••Sub-group analysis of BECAIT showing that angiographicbenefits of bezafibrate were restricted to lesions that were only mildly-to-moderately stenosed.
   Google Scholar
• KEHELY A, MACMAHON M, BARBIR M et al.: Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. Quart. J. Med. (1995) 88:421–427.
   Google Scholar
• ATHYROS VG, PAPAGEORGIOU AA, HATZIKONSTANDI-NOU HA et al.: Safety and efficacy of long-term statin-fibrate combinations in patients with refractory famil-ial combined hyperlipidemia. Am. J. Cardiol (1997) 80:608–613.
   PubMed Web of Science ®Google Scholar
• OLIVER MF: Further observations on the effects of atro-mid and of ethyl chlorophenoxyisobutyrate on serum lipid levels. J. Atheroscler. Res. (1963) 3:427–444.
   PubMedGoogle Scholar
• HASHIM SA, VAN ITALLIE TB: Cholestyramine resin therapy for hypercholesterolemia. JAMA (1965) 192:289–293.
   PubMed Web of Science ®Google Scholar